Thursday, November 15, 2012
OncoSec Medical Inc., of San Diego, reported interim results from a Phase IV trial of NeoPulse in skin cancer at the World Meeting of Interdisciplinary Melanoma and Skin Care Centres and EADO Congress in Barcelona, Spain, showing a complete response greater than 90 percent in basal cell carcinoma patients and 70 percent in squamous cell carcinoma patients at six months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.